S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
S&P 500   4,455.48 (+0.15%)
DOW   34,798.00 (+0.10%)
QQQ   373.33 (+0.09%)
AAPL   146.92 (+0.06%)
MSFT   299.35 (-0.07%)
FB   352.96 (+2.02%)
GOOGL   2,844.30 (+0.71%)
TSLA   774.39 (+2.75%)
AMZN   3,425.52 (+0.28%)
NVDA   220.81 (-1.78%)
BABA   145.08 (-4.04%)
NIO   35.38 (-1.75%)
CGC   13.91 (-4.46%)
GE   103.80 (+0.82%)
MU   74.05 (+0.01%)
AMD   105.80 (-0.33%)
T   27.13 (-0.22%)
F   13.78 (+0.51%)
ACB   5.95 (-3.25%)
DIS   176.00 (-0.14%)
PFE   43.94 (-0.57%)
BA   221.39 (+0.13%)
BAC   42.14 (+1.08%)
NASDAQ:RAPT

RAPT Therapeutics News Headlines

$34.37
+0.15 (+0.44 %)
(As of 09/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$33.17
$34.83
50-Day Range
$29.86
$39.47
52-Week Range
$14.63
$43.26
Volume262,375 shs
Average Volume452,846 shs
Market Capitalization$1.01 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.04

Media Mentions By Week

RAPT Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RAPT
News Sentiment

0.25

0.36

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RAPT Articles
This Week

11

1

RAPT Articles
Average Week

Get RAPT Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

RAPT Therapeutics (NASDAQ RAPT) News Headlines Today

SourceHeadline
Companies Like RAPT Therapeutics (NASDAQ:RAPT) Are In A Position To Invest In GrowthCompanies Like RAPT Therapeutics (NASDAQ:RAPT) Are In A Position To Invest In Growth
finance.yahoo.com - September 23 at 3:38 PM
Contrasting Esperion Therapeutics (NASDAQ:ESPR) & RAPT Therapeutics (NASDAQ:RAPT)Contrasting Esperion Therapeutics (NASDAQ:ESPR) & RAPT Therapeutics (NASDAQ:RAPT)
americanbankingnews.com - September 23 at 1:14 AM
Dont Ignore The Fact That This Insider Just Sold Some Shares In RAPT Therapeutics, Inc. (NASDAQ:RAPT)Don't Ignore The Fact That This Insider Just Sold Some Shares In RAPT Therapeutics, Inc. (NASDAQ:RAPT)
nasdaq.com - September 20 at 6:42 PM
RAPT Therapeutics (NASDAQ:RAPT) Trading Down 7%RAPT Therapeutics (NASDAQ:RAPT) Trading Down 7%
americanbankingnews.com - September 20 at 11:54 AM
RAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology CongressRAPT Therapeutics to Present RPT193 Phase 1b Data at 30th European Academy of Dermatology and Venereology Congress
finance.yahoo.com - September 20 at 8:40 AM
RAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare ConferenceRAPT Therapeutics to Present at the 2021 Cantor Virtual Healthcare Conference
finance.yahoo.com - September 20 at 8:40 AM
RAPT Therapeutics (NASDAQ:RAPT) Shares Gap Up to $37.46RAPT Therapeutics (NASDAQ:RAPT) Shares Gap Up to $37.46
americanbankingnews.com - September 16 at 11:30 AM
Notable Wednesday Option Activity: BCRX, RAPT, TGTNotable Wednesday Option Activity: BCRX, RAPT, TGT
nasdaq.com - September 15 at 5:59 PM
RAPT Therapeutics (NASDAQ:RAPT) Trading Up 4.9%RAPT Therapeutics (NASDAQ:RAPT) Trading Up 4.9%
americanbankingnews.com - September 14 at 1:11 PM
William HoWilliam Ho
benzinga.com - September 10 at 10:47 PM
Chief Medical Officer Of Rapt Therapeutics Makes $108.12 Thousand SaleChief Medical Officer Of Rapt Therapeutics Makes $108.12 Thousand Sale
finance.yahoo.com - September 10 at 10:47 PM
Lycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant VenturesLycia Therapeutics Announces $70 Million Series B Financing Led by Redmile Group with Participation from Founding Investor Versant Ventures
finance.yahoo.com - September 9 at 11:08 AM
RAPT Therapeutics to Present at Upcoming Investor ConferencesRAPT Therapeutics to Present at Upcoming Investor Conferences
finance.yahoo.com - September 3 at 11:13 AM
RAPT Therapeutics (NASDAQ:RAPT) Trading Up 7%RAPT Therapeutics (NASDAQ:RAPT) Trading Up 7%
americanbankingnews.com - September 1 at 2:02 PM
RAPT Therapeutics (RAPT) Buy Rating Reaffirmed at HC WainwrightRAPT Therapeutics' (RAPT) Buy Rating Reaffirmed at HC Wainwright
americanbankingnews.com - August 30 at 1:00 PM
RAPT Therapeutics Reports Second Quarter 2021 Financial ResultsRAPT Therapeutics Reports Second Quarter 2021 Financial Results
finance.yahoo.com - August 11 at 9:46 AM
Analysts Estimate RAPT THERAPTICS (RAPT) to Report a Decline in Earnings: What to Look Out forAnalysts Estimate RAPT THERAPTICS (RAPT) to Report a Decline in Earnings: What to Look Out for
finance.yahoo.com - August 5 at 5:50 PM
RAPT Therapeutics (NASDAQ:RAPT) Shareholders Have Enjoyed A 33% Share Price GainRAPT Therapeutics (NASDAQ:RAPT) Shareholders Have Enjoyed A 33% Share Price Gain
finance.yahoo.com - July 22 at 12:45 PM
RAPT Aug 2021 30.000 putRAPT Aug 2021 30.000 put
ca.finance.yahoo.com - July 18 at 11:14 PM
Monday 7/12 Insider Buying Report: TPL, RAPTMonday 7/12 Insider Buying Report: TPL, RAPT
nasdaq.com - July 12 at 2:08 PM
RAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional SharesRAPT Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
finance.yahoo.com - June 18 at 3:02 PM
RAPT Therapeutics Shares Drop After Stock Offering PricesRAPT Therapeutics Shares Drop After Stock Offering Prices
marketwatch.com - June 16 at 2:41 PM
RAPT Therapeutics Shares Up ~100%; Cantor Raises Price Target To Street High Of $71RAPT Therapeutics Shares Up ~100%; Cantor Raises Price Target To Street High Of $71
benzinga.com - June 16 at 9:41 AM
RAPT Therapeutics Raises $125M Via Equity At 6% DiscountRAPT Therapeutics Raises $125M Via Equity At 6% Discount
markets.businessinsider.com - June 16 at 9:41 AM
Thinking about buying stock in Ocugen, Rapt Therapeutics, ContextLogic, OpGen, or Clean Energy Fuels?Thinking about buying stock in Ocugen, Rapt Therapeutics, ContextLogic, OpGen, or Clean Energy Fuels?
marketwatch.com - June 15 at 11:54 PM
RAPT Therapeutics Announces Pricing of Public Offering of Common StockRAPT Therapeutics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - June 15 at 11:54 PM
RAPT Therapeutics Announces Proposed Public Offering of $125M Of Common StockRAPT Therapeutics Announces Proposed Public Offering of $125M Of Common Stock
benzinga.com - June 15 at 6:54 PM
RAPT Therapeutics Up 104%; Roth Capital Raises Price Target From $38 To $72RAPT Therapeutics Up 104%; Roth Capital Raises Price Target From $38 To $72
benzinga.com - June 15 at 6:54 PM
Noteworthy Tuesday Option Activity: RAPT, ASO, SCCONoteworthy Tuesday Option Activity: RAPT, ASO, SCCO
nasdaq.com - June 15 at 6:54 PM
RAPT Therapeutics (RAPT) is in Overbought Territory: Whats Next?RAPT Therapeutics (RAPT) is in Overbought Territory: What's Next?
nasdaq.com - June 15 at 1:53 PM
RAPT Therapeutics: Promising Clinical Data Merits a Price Target HikeRAPT Therapeutics: Promising Clinical Data Merits a Price Target Hike
finance.yahoo.com - June 15 at 1:53 PM
RAPT Therapeutics Announces Proposed Public Offering of Common StockRAPT Therapeutics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - June 14 at 7:07 PM
Why RAPT Therapeutics Stock Is Surging TodayWhy RAPT Therapeutics Stock Is Surging Today
markets.businessinsider.com - June 14 at 2:06 PM
Stock Alert: Why Shares Of RAPT Therapeutics Are Surging 50%?Stock Alert: Why Shares Of RAPT Therapeutics Are Surging 50%?
markets.businessinsider.com - June 14 at 2:06 PM
Why RAPT Therapeutics Stock Is Crushing It TodayWhy RAPT Therapeutics Stock Is Crushing It Today
finance.yahoo.com - June 14 at 2:06 PM
BRIEF-Rapt Therapeutics Reports Positive Topline Results From Phase 1B Trial Of Rpt193 Monotherapy In Atopic DermatitisBRIEF-Rapt Therapeutics Reports Positive Topline Results From Phase 1B Trial Of Rpt193 Monotherapy In Atopic Dermatitis
msn.com - June 14 at 9:06 AM
RAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic DermatitisRAPT Therapeutics Reports Positive Topline Results from Phase 1b Trial of RPT193 Monotherapy in Atopic Dermatitis
finance.yahoo.com - June 14 at 9:06 AM
RAPT Jun 2021 25.000 putRAPT Jun 2021 25.000 put
ca.finance.yahoo.com - June 12 at 9:44 AM
What Kind Of Shareholders Own RAPT Therapeutics, Inc. (NASDAQ:RAPT)?What Kind Of Shareholders Own RAPT Therapeutics, Inc. (NASDAQ:RAPT)?
finance.yahoo.com - June 7 at 6:05 PM
Rapt Therapeutics IncRapt Therapeutics Inc
reuters.com - May 22 at 1:19 AM
RAPT Therapeutics to Present at the UBS Global Healthcare Virtual ConferenceRAPT Therapeutics to Present at the UBS Global Healthcare Virtual Conference
finance.yahoo.com - May 20 at 6:51 PM
Implied Volatility Surging for RAPT Therapeutics (RAPT) Stock OptionsImplied Volatility Surging for RAPT Therapeutics (RAPT) Stock Options
finance.yahoo.com - May 19 at 1:57 PM
RAPT Therapeutics Reports First Quarter 2021 Financial ResultsRAPT Therapeutics Reports First Quarter 2021 Financial Results
finance.yahoo.com - May 11 at 8:22 AM
RAPT THERAPTICS (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q1 ReleaseRAPT THERAPTICS (RAPT) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
finance.yahoo.com - May 6 at 5:48 PM
Notable Friday Option Activity: GS, RAPT, AMDNotable Friday Option Activity: GS, RAPT, AMD
nasdaq.com - April 30 at 8:28 PM
Do Options Traders Know Something About RAPT Therapeutics (RAPT) Stock We Dont?Do Options Traders Know Something About RAPT Therapeutics (RAPT) Stock We Don't?
finance.yahoo.com - April 12 at 9:40 AM
Who Has Been Buying RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares?Who Has Been Buying RAPT Therapeutics, Inc. (NASDAQ:RAPT) Shares?
finance.yahoo.com - April 8 at 10:24 AM
RAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic DermatitisRAPT Therapeutics Completes Enrollment in Phase 1b Trial of RPT193 in Atopic Dermatitis
finance.yahoo.com - March 22 at 12:25 PM
RAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial ResultsRAPT Therapeutics Reports Fourth Quarter and Year End 2020 Financial Results
finance.yahoo.com - March 11 at 8:34 AM
RAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACRRAPT Therapeutics to Report Promising Preclinical Studies Supporting its Pipeline of Immunotherapy Platforms at AACR
finance.yahoo.com - March 10 at 7:56 PM
Get RAPT Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RAPT and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/24/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.